Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression

Journal of Advanced Research

Volumn 7, Issue 5, 2016, Pages 661-670

  Ibrahim, Sherif A ^a   El Ghonaimy, Eslam A ^a   Hassan, Hebatallah ^a   Mahana, Noha ^a   Mahmoud, Mahmoud Abdelbaky ^b   El Mamlouk, Tahani ^a   El Shinawi, Mohamed ^b   Mohamed, Mona M ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Cathepsin B; Epithelial mesenchymal transition; Hormonal receptor positive breast cancer; IL 6; Invasion; Lymph node metastasis

Indexed keywords

EID: 84978034010     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2016.06.007     Document Type: Article

References (54)

1. Youlden D.R., Cramb S.M., Dunn N.A., Muller J.M., Pyke C.M., Baade P.D. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 2012, 36:237-248.
2. Salhia B., Tapia C., Ishak E.A., Gaber S., Berghuis B., Hussain K.H., et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Womens Health 2011, 11:44.
3. Michaelson J.S., Silverstein M., Sgroi D., Cheongsiatmoy J.A., Taghian A., Powell S., et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer 2003, 98:2133-2143.
4. Nouh M.A., Ismail H., El-Din N.H., El-Bolkainy M.N. Lymph node metastasis in breast carcinoma: clinicopathologic correlations in 3747 patients. J Egypt Natl Canc Inst 2004, 16(1):50-56.
5. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187.
6. Fisher B., Bauer M., Wickerham D.L., Redmond C.K., Fisher E.R., Cruz A.B., et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983, 52:1551-1557.
7. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006, 6:764-775.
8. Victor B.C., Anbalagan A., Mohamed M.M., Sloane B.F., Cavallo-Medved D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res 2011, 13:R115.
9. Nouh M.A., Mohamed M.M., El-Shinawi M., Shaalan M.A., Cavallo-Medved D., Khaled H.M., et al. Cathepsin B: a potential prognostic marker for inflammatory breast cancer. J Transl Med 2011, 9:1.
10. Wickramasinghe N.S., Nagaraj N.S., Vigneswaran N., Zacharias W. Cathepsin B promotes both motility and invasiveness of oral carcinoma cells. Arch Biochem Biophys 2005, 436:187-195.
11. Wickramasinghe N.S., Banerjee K., Nagaraj N.S., Vigneswaran N., Zacharias W. Hypoxia alters cathepsin B/inhibitor profiles in oral carcinoma cell lines. Anticancer Res 2005, 25:2841-2849.
12. Campo E., Munoz J., Miquel R., Palacin A., Cardesa A., Sloane B.F., et al. Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol 1994, 145:301-309.
13. Werle B., Lotterle H., Schanzenbacher U., Lah T.T., Kalman E., Kayser K., et al. Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients. Br J Cancer 1999, 81:510-519.
14. Scorilas A., Fotiou S., Tsiambas E., Yotis J., Kotsiandri F., Sameni M., et al. Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients. Biol Chem 2002, 383:1297-1303.
15. Devetzi M., Scorilas A., Tsiambas E., Sameni M., Fotiou S., Sloane B.F., et al. Cathepsin B protein levels in endometrial cancer: potential value as a tumour biomarker. Gynecol Oncol 2009, 112:531-536.
16. Sameni M., Elliott E., Ziegler G., Fortgens P.H., Dennison C., Sloane B.F. Cathepsin B and D are localized at the surface of human breast cancer cells. Pathol Oncol Res 1995, 1:43-53.
17. Warwas M., Haczynska H., Gerber J., Nowak M. Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem 1997, 35:301-304.
18. Sinha A.A., Jamuar M.P., Wilson M.J., Rozhin J., Sloane B.F. Plasma membrane association of cathepsin B in human prostate cancer: biochemical and immunogold electron microscopic analysis. Prostate 2001, 49:172-184.
19. Koblinski J.E., Ahram M., Sloane B.F. Unraveling the role of proteases in cancer. Clin Chim Acta 2000, 291:113-135.
20. Roshy S., Sloane B.F., Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev 2003, 22:271-286.
21. Cavallo-Medved D., Mai J., Dosescu J., Sameni M., Sloane B.F. Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J Cell Sci 2005, 118:1493-1503.
22. Cavallo-Medved D., Dosescu J., Linebaugh B.E., Sameni M., Rudy D., Sloane B.F. Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. Neoplasia 2003, 5:507-519.
23. Purohit A., Singh A., Ghilchik M.W., Serlupi-Crescenzi O., Reed M.J. Inhibition of IL-6+IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts. Br J Cancer 2003, 88:630-635.
24. Yamaguchi T., Naruishi K., Arai H., Nishimura F., Takashiba S. IL-6/sIL-6R enhances cathepsin B and L production via caveolin-1-mediated JNK-AP-1 pathway in human gingival fibroblasts. J Cell Physiol 2008, 217:423-432.
25. Chae H.J., Ha K.C., Lee G.Y., Yang S.K., Yun K.J., Kim E.C., et al. Interleukin-6 and cyclic AMP stimulate release of cathepsin B in human osteoblasts. Immunopharmacol Immunotoxicol 2007, 29:155-172.
26. Mohamed M.M., Cavallo-Medved D., Sloane B.F. Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer. Biol Chem 2008, 389:1117-1121.
27. Mohamed M.M., Cavallo-Medved D., Rudy D., Anbalagan A., Moin K., Sloane B.F. Interleukin-6 increases expression and secretion of cathepsin B by breast tumor-associated monocytes. Cell Physiol Biochem 2010, 25:315-324.
28. Linebaugh B.E., Sameni M., Day N.A., Sloane B.F., Keppler D. Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem 1999, 264:100-109.
29. Sameni M., Moin K., Sloane B.F. Imaging proteolysis by living human breast cancer cells. Neoplasia 2000, 2:496-504.
30. Narita D., Seclaman E., Ursoniu S., Ilina R., Cireap N., Anghel A. Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls. Rom J Morphol Embryol 2011, 52:1261-1267.
31. Landskron G., De la Fuente M., Thuwajit P., Thuwajit C., Hermoso M.A. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014, 2014:149185.
32. Walter M., Liang S., Ghosh S., Hornsby P.J., Li R. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 2009, 28:2745-2755.
33. Schafer Z.T., Brugge J.S. IL-6 involvement in epithelial cancers. J Clin Invest 2007, 117:3660-3663.
34. Knupfer H., Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007, 102:129-135.
35. Garcia-Tunon I., Ricote M., Ruiz A., Fraile B., Paniagua R., Royuela M. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 2005, 47:82-89.
36. Sullivan N.J., Sasser A.K., Axel A.E., Vesuna F., Raman V., Ramirez N., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
37. Zhang M., Gong W., Zhang Y., Yang Y., Zhou D., Weng M., et al. Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer. Mol Med Rep 2015, 11:3539-3546.
38. Buck M.R., Karustis D.G., Day N.A., Honn K.V., Sloane B.F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 1992, 282(Pt 1):273-278.
39. Castiglioni T., Merino M.J., Elsner B., Lah T.T., Sloane B.F., Emmert-Buck M.R. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol 1994, 25:857-862.
40. Premzl A., Zavasnik-Bergant V., Turk V., Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp Cell Res 2003, 283:206-214.
41. Gerber A., Wille A., Welte T., Ansorge S., Buhling F. Interleukin-6 and transforming growth factor-beta 1 control expression of cathepsins B and L in human lung epithelial cells. J Interferon Cytokine Res 2001, 21:11-19.
42. Ebisui C., Tsujinaka T., Morimoto T., Kan K., Iijima S., Yano M., et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci (Lond) 1995, 89:431-439.
43. Kossakowska A.E., Edwards D.R., Prusinkiewicz C., Zhang M.C., Guo D., Urbanski S.J., et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999, 94:2080-2089.
44. Sundelin K., Roberg K., Grenman R., Hakansson L. Effects of cytokines on matrix metalloproteinase expression in oral squamous cell carcinoma in vitro. Acta Otolaryngol 2005, 125:765-773.
45. Foekens J.A., Kos J., Peters H.A., Krasovec M., Look M.P., Cimerman N., et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998, 16:1013-1021.
46. Zhang G.J., Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999, 19:1427-1432.
47. Salgado R., Junius S., Benoy I., Van Dam P., Vermeulen P., Van Marck E., et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003, 103:642-646.
48. Dethlefsen C., Hojfeldt G., Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 2013, 138:657-664.
49. Martin S.L., Moffitt K.L., McDowell A., Greenan C., Bright-Thomas R.J., Jones A.M., et al. Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatr Pulmonol 2010, 45:860-868.
50. Bien S., Ritter C.A., Gratz M., Sperker B., Sonnemann J., Beck J.F., et al. Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Mol Pharmacol 2004, 65:1092-1102.
51. Voorhees P.M., Manges R.F., Sonneveld P., Jagannath S., Somlo G., Krishnan A., et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013, 161:357-366.
52. Hunsucker S.A., Magarotto V., Kuhn D.J., Kornblau S.M., Wang M., Weber D.M., et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011, 152:579-592.
53. Hassan H., Greve B., Pavao M.S., Kiesel L., Ibrahim S.A., Gotte M. Syndecan-1 modulates beta-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J 2013, 280:2216-2227.
54. Casneuf T., Axel A.E., King P., Alvarez J.D., Werbeck J.L., Verhulst T., et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-alpha-positive breast cancer. Breast Cancer (Dove Med Press) 2016, 8:13-27.